234 related articles for article (PubMed ID: 30731342)
1. The effect of somatostatin analogues on Ki-67 levels in GH-secreting adenomas.
Selek A; Cetinarslan B; Canturk Z; Tarkun I; Hanazay Y; Vural C; Anik I; Ceylan S
Growth Horm IGF Res; 2019 Apr; 45():1-5. PubMed ID: 30731342
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant.
Franck SE; Gatto F; van der Lely AJ; Janssen JAMJL; Dallenga AHG; Nagtegaal AP; Hofland LJ; Neggers SJCMM
Neuroendocrinology; 2017; 105(1):44-53. PubMed ID: 27455094
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of the Ki-67 labeling index in growth hormone-secreting pituitary adenomas.
Fusco A; Zatelli MC; Bianchi A; Cimino V; Tilaro L; Veltri F; Angelini F; Lauriola L; Vellone V; Doglietto F; Ambrosio MR; Maira G; Giustina A; degli Uberti EC; Pontecorvi A; De Marinis L
J Clin Endocrinol Metab; 2008 Jul; 93(7):2746-50. PubMed ID: 18460561
[TBL] [Abstract][Full Text] [Related]
4. Preoperative Somatostatin Analogue Treatment Might Trigger Apoptosis and Autophagy in Tumor Tissues of Patients with Acromegaly: A Pilot Study.
Dagistanli FK; Ozkaya HM; Kucukyoruk B; Biceroglu H; Metin D; Gazioglu N; Oz B; Kadioglu P; Ozturk M
Exp Clin Endocrinol Diabetes; 2018 Mar; 126(3):168-175. PubMed ID: 27322826
[TBL] [Abstract][Full Text] [Related]
5. T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly.
Potorac I; Petrossians P; Daly AF; Alexopoulou O; Borot S; Sahnoun-Fathallah M; Castinetti F; Devuyst F; Jaffrain-Rea ML; Briet C; Luca F; Lapoirie M; Zoicas F; Simoneau I; Diallo AM; Muhammad A; Kelestimur F; Nazzari E; Centeno RG; Webb SM; Nunes ML; Hana V; Pascal-Vigneron V; Ilovayskaya I; Nasybullina F; Achir S; Ferone D; Neggers SJ; Delemer B; Petit JM; Schöfl C; Raverot G; Goichot B; Rodien P; Corvilain B; Brue T; Schillo F; Tshibanda L; Maiter D; Bonneville JF; Beckers A
Endocr Relat Cancer; 2016 Nov; 23(11):871-881. PubMed ID: 27649724
[TBL] [Abstract][Full Text] [Related]
6. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs.
Petrossians P; Borges-Martins L; Espinoza C; Daly A; Betea D; Valdes-Socin H; Stevenaert A; Chanson P; Beckers A
Eur J Endocrinol; 2005 Jan; 152(1):61-6. PubMed ID: 15762188
[TBL] [Abstract][Full Text] [Related]
7. Magnetic resonance spectroscopy may serve as a presurgical predictor of somatostatin analog therapy response in patients with growth hormone-secreting pituitary macroadenomas.
Hu J; Yan J; Zheng X; Zhang Y; Ran Q; Tang X; Shu T; Shen R; Duan L; Zhang D; Guo Q; Zhang W; Yang H; Li S
J Endocrinol Invest; 2019 Apr; 42(4):443-451. PubMed ID: 30171531
[TBL] [Abstract][Full Text] [Related]
8. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly.
Colao A; Attanasio R; Pivonello R; Cappabianca P; Cavallo LM; Lasio G; Lodrini A; Lombardi G; Cozzi R
J Clin Endocrinol Metab; 2006 Jan; 91(1):85-92. PubMed ID: 16263832
[TBL] [Abstract][Full Text] [Related]
9. Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.
Koylu B; Firlatan B; Sendur SN; Oguz SH; Dagdelen S; Erbas T
Endocrine; 2023 Mar; 79(3):545-553. PubMed ID: 36318446
[TBL] [Abstract][Full Text] [Related]
10. An analysis of granulation patterns, MIB-1 proliferation indices and p53 expression in 101 patients with acromegaly.
Sarkar S; Chacko AG; Chacko G
Acta Neurochir (Wien); 2014 Dec; 156(12):2221-30; discussion 2230. PubMed ID: 25238988
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
12. DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.
Plöckinger U; Hoffmann U; Geese M; Lupp A; Buchfelder M; Flitsch J; Vajkoczy P; Jakob W; Saeger W; Schulz S; Dohrmann C
Eur J Endocrinol; 2012 Feb; 166(2):223-34. PubMed ID: 22065857
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes.
Bianchi A; Valentini F; Iuorio R; Poggi M; Baldelli R; Passeri M; Giampietro A; Tartaglione L; Chiloiro S; Appetecchia M; Gargiulo P; Fabbri A; Toscano V; Pontecorvi A; De Marinis L
J Exp Clin Cancer Res; 2013 Jun; 32(1):40. PubMed ID: 23799893
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of dose escalation and surgical debulking in patients with acromegaly treated with somatostatin analogs in a Romanian tertiary care center.
Gheorghiu ML; Găloiu S; Vintilă M; Purice M; Hortopan D; Dumitraşcu A; Coculescu M; Poiană C
Hormones (Athens); 2016 Apr; 15(2):224-234. PubMed ID: 27376425
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical GH Increase During OGTT Is Associated With First-Generation Somatostatin Analog Responsiveness in Acromegaly.
Scaroni C; Albiger N; Daniele A; Dassie F; Romualdi C; Vazza G; Regazzo D; Ferraù F; Barresi V; Maffeis V; Gardiman MP; Cannavò S; Maffei P; Ceccato F; Losa M; Occhi G
J Clin Endocrinol Metab; 2019 Mar; 104(3):856-862. PubMed ID: 30285115
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of microRNAs in GH-secreting pituitary adenomas.
Mao ZG; He DS; Zhou J; Yao B; Xiao WW; Chen CH; Zhu YH; Wang HJ
Diagn Pathol; 2010 Dec; 5():79. PubMed ID: 21138567
[TBL] [Abstract][Full Text] [Related]
17. Giant GH-secreting pituitary adenomas: management of rare and aggressive pituitary tumors.
Shimon I; Jallad RS; Fleseriu M; Yedinak CG; Greenman Y; Bronstein MD
Eur J Endocrinol; 2015 Jun; 172(6):707-13. PubMed ID: 25792375
[TBL] [Abstract][Full Text] [Related]
18. Treatment of acromegaly in the era of personalized and predictive medicine.
Puig Domingo M
Clin Endocrinol (Oxf); 2015 Jul; 83(1):3-14. PubMed ID: 25640882
[TBL] [Abstract][Full Text] [Related]
19. Percent reduction of growth hormone levels correlates closely with percent resected tumor volume in acromegaly.
Schwyzer L; Starke RM; Jane JA; Oldfield EH
J Neurosurg; 2015 Apr; 122(4):798-802. PubMed ID: 25423276
[TBL] [Abstract][Full Text] [Related]
20. Presurgical treatment with somatostatin analogues in growth hormone-secreting pituitary adenomas: A long-term single-center experience.
Lv L; Hu Y; Zhou P; Zhang S; Yin S; Zhang N; Jiang S
Clin Neurol Neurosurg; 2018 Apr; 167():24-30. PubMed ID: 29433055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]